<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970824</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P17 1.1</org_study_id>
    <nct_id>NCT03970824</nct_id>
  </id_info>
  <brief_title>To Compare the Pharmacokinetics and Safety of CT-P17 and Humira (US Licensed Humira and EU-approved Humira) in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of CT-P17 and Humira (US Licensed Humira and EU-approved Humira) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, Randomized, Double-blind, Three-arm, Parallel group, Single-dose Study to Compare
      the Pharmacokinetics and Safety of CT-P17 and Humira (US licensed Humira and EU-approved
      Humira) in Healthy Subjects
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 31, 2019</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Actual">November 13, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve (AUC)</measure>
    <time_frame>up to Day 71</time_frame>
    <description>To demonstrate the PK similarity in terms of area under the concentration-time curve (AUC) from zero to infinity (AUC0-inf), AUC from zero to the last quantifiable concentration (AUC0-last)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum serum concentration (Cmax)</measure>
    <time_frame>up to Day 71</time_frame>
    <description>To demonstrate the PK similarity in terms of maximum serum concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>up to Day 71</time_frame>
    <description>The immunogenicity of CT-P17 and reference drugs will be assessed at baseline and post treatment serum measures by a validated immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional Pharmacokinetics</measure>
    <time_frame>up to Day 71</time_frame>
    <description>To assess the additional PK of study drugs: such as Time to Cmax (Tmax)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CT-P17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a single subcutaneous (SC) injection via pre-filled syringe (PFS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-licensed Humira</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single subcutaneous (SC) injection via pre-filled syringe (PFS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU approved Humira</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>a single subcutaneous (SC) injection via pre-filled syringe (PFS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P17</intervention_name>
    <description>40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS</description>
    <arm_group_label>CT-P17</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US-licensed Humira</intervention_name>
    <description>40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS</description>
    <arm_group_label>US-licensed Humira</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU approved Humira</intervention_name>
    <description>40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS</description>
    <arm_group_label>EU approved Humira</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female subjects, between the ages of 19 and 55 years

          -  BMI between 18.0 and 29.9 kg/m2, both inclusive, when rounded to the nearest tenth

        Exclusion Criteria:

          -  Clinically significant allergic reactions, hypersensitivity

          -  A medical history and/or condition that is considered significant

          -  A disease classed as significant by the Investigator

          -  Planning to be pregnant or father a child or donate sperm within 5 month after
             administration

          -  Undergone treatment with an investigational drug or participated in another clinical
             trial within 180 days or 5 half-lives (whichever is longer)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Joon Lee</last_name>
    <role>Study Director</role>
    <affiliation>Celltrion, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <zip>47392</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Hospital</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13520</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

